Hints and tips:
Related Topics
...Médecins Sans Frontières refused to sign a non-disclosure agreement on pricing requested by ViiV for an access deal in Mozambique and other countries....
...Some good news A vaccine-like drug administered once a year to prevent HIV could be ready just after 2030, according to drugmaker ViiV....
...A vaccine-like drug to prevent HIV, the virus that can lead to Aids, administered once a year, could be ready just after 2030, according to developer ViiV....
...However, ViiV alone cannot satisfy global demand. The need for effective and easily accessible PrEP continues to be strong....
...ViiV is not the only one in this field. Merck and Gilead Sciences, for example, are working together to develop long-acting HIV treatments....
...“We need new tools in our toolbox and I think this is unquestionably the most powerful tool,” Kim Smith, head of research and development at ViiV, told the Financial Times....
...She stressed that GSK had a good record on partnerships in particular, including its joint venture with ViiV Healthcare on HIV medicines, and its more recent collaboration with German mRNA vaccine maker...
...GSK’s Viiv Healthcare unit has reached a $1.25bn settlement with Gilead Sciences over a patent dispute....
...One of these drugs, called cabotegravir, is made by ViiV, which has submitted data to the US Food and Drug Administration for approval....
...Science round up GlaxoSmithKline’s ViiV Healthcare is “actively negotiating” a voluntary licence on the patents for its injectable HIV prevention drug to make it more widely available in poorer nations,...
...It is made by ViiV Healthcare, a company that is majority-owned by GSK and also backed by Pfizer and Shionogi....
...The $28bn HIV market is dominated by Gilead, which has a 53 per cent share, more than double ViiV’s 22 per cent....
...Kimberly Smith, head of global research and medical strategy at ViiV, said test patients had liked the new regimen....
...She also suggested that the ViiV medicine would beat Gilead’s medication, Biktarvy, on price, saying it would be the lowest-cost single-tablet regimen of its kind....
...She highlighted data published on Wednesday that showed an HIV treatment developed by ViiV Healthcare, which is majority owned by GSK, containing only two drugs was as effective as the traditional three-drug...
...The company also named Deborah Waterhouse, chief executive of Glaxo-controlled ViiV Healthcare, to the board....
...In the case of the injectable version, ViiV wants to be able to free HIV patients from having to take daily treatment....
...People close to the negotiations that unfolded at speed in recent weeks say that a crucial factor in consummating the deal was the two companies’ existing joint venture ViiV Healthcare, which specialises...
...Following the success of the trials, Viiv expects to apply for regulatory approval to market the monthly injectable combination this year....
...ViiV said the Gemini studies “demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination....
...Andrew Baum, at Citi, said that with the company facing “increasing anticipated pressure on ViiV [its HIV business] and respiratory, Shingrix becomes the critical driver of near term earnings outlook”....
...But Viiv's part of that....
...Other large drugmakers, including Allergan, GlaxoSmithKline, Gilead, Shire, Biogen, Teva, Baxter and Viiv also increased the US list prices of their medicines on January 1, according to the data....
...Guests include Deborah Waterhouse of ViiV Healthcare and Yusef Azad of the National Aids Trust....
...GSK’s 10 per cent discount to its sector adequately discounts risks around ViiV, the HIV franchise that provides around a third of group earnings, which is facing new competition from Gilead, UBS said....
International Edition